Illumina, Inc. vs Ventas Inc. Common Stock — how do they compare? Illumina, Inc. trades at $274 (market cap $39.95B), while Ventas Inc. Common Stock trades at $81.95 (market cap $41.94B). The key difference: Illumina, Inc. and Ventas Inc. Common Stock are close in size by market cap, and Ventas Inc. Common Stock pays a 2.54% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Ventas Inc. Common Stock for 0 Days on average.
| ILMN | VTR | |
|---|---|---|
Market Cap | $39.95B | $41.94B |
Volume | 3,169,503 | 4,588,793 |
Sector | Health | Real Estate |
52-Week High | $293.69 | $100.53 |
52-Week Low | $91.00 | $67.45 |
Typical Hold Time | 83 Days | 0 Days |
Enterprise Value | $41.31B | $54.66B |
Dividend Yield | — | 2.54% |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Ventas is a real estate investment trust focused on healthcare properties. Its portfolio includes senior housing, medical office buildings, and research-related facilities.
Read more on VTR →